Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
A Logo

Agilent Technologies, Inc.

A

Laboratory Analytical Instruments

Mkt Cap

$41.15B

PE

33.30

Debt

$2.555B

Cash

$1.75B

EV

$41.96B

FCF

$1.649B

Market Cap

$41.15B

P/E Ratio

33.30

Debt

$2.555B

Cash

$1.75B

EV

$41.96B

FCF

$1.649B
Charts data: {"Earnings":[{"time":"2014-10-30","value":504000000},{"time":"2015-10-30","value":401000000},{"time":"2016-10-30","value":462000000},{"time":"2017-10-30","value":684000000},{"time":"2018-10-30","value":316000000},{"time":"2019-10-30","value":1071000000},{"time":"2020-10-30","value":719000000},{"time":"2021-10-30","value":1210000000},{"time":"2022-10-30","value":1254000000},{"time":"2023-10-30","value":1240000000}],"Sales":[{"time":"2014-10-30","value":4048000000},{"time":"2015-10-30","value":4038000000},{"time":"2016-10-30","value":4202000000},{"time":"2017-10-30","value":4472000000},{"time":"2018-10-30","value":4914000000},{"time":"2019-10-30","value":5163000000},{"time":"2020-10-30","value":5339000000},{"time":"2021-10-30","value":6319000000},{"time":"2022-10-30","value":6848000000},{"time":"2023-10-30","value":6833000000}],"Net Margins":[{"time":"2014-10-30","value":0.12450592885375494},{"time":"2015-10-30","value":0.0993065874195146},{"time":"2016-10-30","value":0.1099476439790576},{"time":"2017-10-30","value":0.15295169946332737},{"time":"2018-10-30","value":0.06430606430606431},{"time":"2019-10-30","value":0.2074375363160953},{"time":"2020-10-30","value":0.13466941374789287},{"time":"2021-10-30","value":0.1914859946194018},{"time":"2022-10-30","value":0.18311915887850466},{"time":"2023-10-30","value":0.18147226693985072}],"Assets":[{"time":"2014-10-30","value":10831000000},{"time":"2015-10-30","value":7479000000},{"time":"2016-10-30","value":7802000000},{"time":"2017-10-30","value":8426000000},{"time":"2018-10-30","value":8541000000},{"time":"2019-10-30","value":9452000000},{"time":"2020-10-30","value":9627000000},{"time":"2021-10-30","value":10705000000},{"time":"2022-10-30","value":10532000000},{"time":"2023-10-30","value":10763000000}],"Stockholders Equity":[{"time":"2014-10-30","value":5301000000},{"time":"2015-10-30","value":4170000000},{"time":"2016-10-30","value":4246000000},{"time":"2017-10-30","value":4835000000},{"time":"2018-10-30","value":4571000000},{"time":"2019-10-30","value":4748000000},{"time":"2020-10-30","value":4873000000},{"time":"2021-10-30","value":5389000000},{"time":"2022-10-30","value":5305000000},{"time":"2023-10-30","value":5845000000}],"ROE":[{"time":"2014-10-30","value":0.09507640067911714},{"time":"2015-10-30","value":0.0961630695443645},{"time":"2016-10-30","value":0.10880829015544041},{"time":"2017-10-30","value":0.14146845915201656},{"time":"2018-10-30","value":0.0691314810763509},{"time":"2019-10-30","value":0.22556866048862678},{"time":"2020-10-30","value":0.14754771188179766},{"time":"2021-10-30","value":0.22453145295973279},{"time":"2022-10-30","value":0.23638077285579642},{"time":"2023-10-30","value":0.21214713430282292}],"ROA":[{"time":"2014-10-30","value":0.12205705844335703},{"time":"2015-10-30","value":0.1025538173552614},{"time":"2016-10-30","value":0.11009997436554729},{"time":"2017-10-30","value":0.11559458817944458},{"time":"2018-10-30","value":0.11954103734925653},{"time":"2019-10-30","value":0.10505713076597545},{"time":"2020-10-30","value":0.09556455801391918},{"time":"2021-10-30","value":0.12704343764595982},{"time":"2022-10-30","value":0.15362704139764527},{"time":"2023-10-30","value":0.1254297129053238}]}

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Sector

  • AVTR Logo

    AVTR

  • BIO Logo

    BIO

  • BRKR Logo

    BRKR

  • CTKB Logo

    CTKB

  • EYPT Logo

    EYPT

  • ILMN Logo

    ILMN

  • MTD Logo

    MTD

  • NAUT Logo

    NAUT

  • PACB Logo

    PACB

  • QTRX Logo

    QTRX

Growth

%

%

Discount

%

%

Multiple

g\r+10%+11%+12%+13%+14%
0%109887
+1%1110988
+2%13111098
+3%141311109
+4%1714121110
Years012345678910TV
FCF$1.649B$1.899B$2.166B$2.446B$2.734B$3.026B$3.314B$3.592B$3.853B$4.089B$4.294B$42.94B
DCF$1.652B$1.638B$1.608B$1.563B$1.504B$1.433B$1.35B$1.26B$1.162B$1.061B$10.61B
Value$24.84B

In the chart Earnings are multiplied by this value.

Earnings Growth 18%
Earnings Stability 63%


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years10-201510-201610-201710-201810-201910-202010-202110-202210-2023TTM
Net Margin9.9%11%15%6.4%21%13%19%18%18%18%
ROA10%11%12%12%11%9.6%13%15%13%12%
ROE9.6%11%14%6.9%23%15%22%24%21%20%

What is the average Net Margin?

The average Net Margin over the past 5 years is +16.04%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +1.63%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is +12.1%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +0.59%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is +18.59%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +2.36%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years10-201510-201610-201710-201810-201910-202010-202110-202210-2023TTM
Debt FCF4.212.922.821.982.782.942.102.711.861.55
Debt Equity0.400.450.420.390.510.480.510.520.470.41
MIN
Graham Stability--100%61%100%100%100%100%100%61%

What is the Debt/FCF?

The Debt/FCF trailing twelve month is 1.55.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -0.05.

What is the Graham’s Stability?

Graham’s Stability measure stands at 0.61.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years10-201610-201810-202010-2022Trend
Revenue7.2%6.8%8.6%-0.22%0.51%
Net Income15%31%20%-1.1%1.7%
Stockholders Equity4.7%5%6.3%10%2%
FCF12%10%22%44%1.2%

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +6.82%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is +0.51%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is +31.45%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is +1.73%.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +5.04%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is +1.96%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is +10.13%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is +1.24%.